Investigations into Proposed Buyouts of Optimer Pharmaceuticals, Inc., Trius Therapeutics, Inc. & Maidenform Brands, Inc. Ann...
01 August 2013 - 9:12PM
Business Wire
Holzer Holzer & Fistel, LLC is investigating potential
shareholder claims on behalf of investors who currently own Optimer
Pharmaceuticals, Inc., Trius Therapeutics, Inc. or Maidenform
Brands, Inc. common stock. The firm is investigating whether the
boards of directors complied with their fiduciary duties in
approving the buyouts of their respective companies. Investors who
own stock in any of these companies that would like to discuss
their legal rights are encouraged to contact Holzer Holzer &
Fistel, LLC and its attorneys Michael I. Fistel, Jr., Esq.
(mfistel@holzerlaw.com) or Marshall P. Dees, Esq.
(mdees@holzerlaw.com) via email or via toll-free telephone at (888)
508-6832.
Optimer Pharmaceuticals, Inc.
On July 30, 2013, it was announced that Cubist Pharmaceuticals
would acquire all outstanding shares of Optimer Pharmaceuticals
(NASDAQ: OPTR) for $10.75 per share, plus a Contingency Value Right
that would entitle the holder to an additional $5 per share if net
sales targets for its drug DIFICID are achieved. The firm’s
investigation seeks to determine, among other things, whether the
consideration to be paid to Optimer shareholders is fair and
adequate.
Trius Therapeutics, Inc.
Also on July 30, 2013, Cubist Pharmaceuticals announced that it
would purchase Trius Therapeutics (NASDAQ: TSRX) common stock for
$13.50 per share, with an additional Contingency Value Right of $2
per share. The firm’s investigation into this proposed transaction
seeks to determine if the price per share to be paid by Cubist to
TSRX shareholders is fair and adequate.
Maidenform Brands, Inc.
On July 24, 2013, Maidenform Brands, Inc. (NYSE: MFB) announced
HanesBrands was purchasing all of its outstanding stock for $23.50
per share. The firm is investigating whether Maidenform’s board of
directors complied with their fiduciary duties in approving the
proposed buyout.
Holzer Holzer & Fistel, LLC dedicates its practice to
vigorous representation of shareholders and investors in litigation
nationwide, including shareholder class action and derivative
litigation. More information about the firm is available through
its website, www.holzerlaw.com and upon request from the
firm. Holzer Holzer & Fistel, LLC has paid for the
dissemination of this promotional communication, and Michael I.
Fistel, Jr. is the attorney responsible for its content.
Maidenform (NYSE:MFB)
Historical Stock Chart
Von Dez 2024 bis Jan 2025
Maidenform (NYSE:MFB)
Historical Stock Chart
Von Jan 2024 bis Jan 2025
Echtzeit-Nachrichten über Maidenform Brands, Inc. (New York Börse): 0 Nachrichtenartikel
Weitere Maidenform Brands, Inc. News-Artikel